| 0024-5901 | Praluent | alirocumab | Sanofi-Aventis U.S. LLC | BLA | Current |
| 0024-5901 | Praluent | alirocumab | Sanofi-Aventis U.S. LLC | BLA | Current |
| 0024-5901 | Praluent | alirocumab | Sanofi-Aventis U.S. LLC | BLA | Current |
| 0024-5901 | Praluent | alirocumab | Sanofi-Aventis U.S. LLC | BLA | Current |
| 0024-5901 | Praluent | alirocumab | Sanofi-Aventis U.S. LLC | BLA | Current |
| 0024-5901 | Praluent | alirocumab | Sanofi-Aventis U.S. LLC | BLA | Current |
| 0024-5901 | Praluent | alirocumab | Sanofi-Aventis U.S. LLC | BLA | Current |
| 0024-5901 | Praluent | alirocumab | Sanofi-Aventis U.S. LLC | BLA | Current |
| 0024-5901 | Praluent | alirocumab | Sanofi-Aventis U.S. LLC | BLA | Current |
| 0024-5901 | Praluent | alirocumab | Sanofi-Aventis U.S. LLC | BLA | Current |
| 0024-5901 | Praluent | alirocumab | Sanofi-Aventis U.S. LLC | BLA | Current |
| 0024-5901 | Praluent | alirocumab | Sanofi-Aventis U.S. LLC | BLA | Current |
| 0024-5902 | Praluent | alirocumab | Sanofi-Aventis U.S. LLC | BLA | Current |
| 0024-5902 | Praluent | alirocumab | Sanofi-Aventis U.S. LLC | BLA | Current |
| 0024-5902 | Praluent | alirocumab | Sanofi-Aventis U.S. LLC | BLA | Current |
| 0024-5902 | Praluent | alirocumab | Sanofi-Aventis U.S. LLC | BLA | Current |
| 0024-5902 | Praluent | alirocumab | Sanofi-Aventis U.S. LLC | BLA | Current |
| 0024-5902 | Praluent | alirocumab | Sanofi-Aventis U.S. LLC | BLA | Current |
| 0024-5902 | Praluent | alirocumab | Sanofi-Aventis U.S. LLC | BLA | Current |
| 0024-5902 | Praluent | alirocumab | Sanofi-Aventis U.S. LLC | BLA | Current |
| 0024-5902 | Praluent | alirocumab | Sanofi-Aventis U.S. LLC | BLA | Current |
| 0024-5902 | Praluent | alirocumab | Sanofi-Aventis U.S. LLC | BLA | Current |
| 0024-5902 | Praluent | alirocumab | Sanofi-Aventis U.S. LLC | BLA | Current |
| 0024-5902 | Praluent | alirocumab | Sanofi-Aventis U.S. LLC | BLA | Current |
| 0024-5903 | Praluent | alirocumab | Sanofi-Aventis U.S. LLC | BLA | Current |
| 0024-5903 | Praluent | alirocumab | Sanofi-Aventis U.S. LLC | BLA | Current |
| 0024-5903 | Praluent | alirocumab | Sanofi-Aventis U.S. LLC | BLA | Current |
| 0024-5903 | Praluent | alirocumab | Sanofi-Aventis U.S. LLC | BLA | Current |
| 0024-5903 | Praluent | alirocumab | Sanofi-Aventis U.S. LLC | BLA | Current |
| 0024-5903 | Praluent | alirocumab | Sanofi-Aventis U.S. LLC | BLA | Current |
| 0024-5903 | Praluent | alirocumab | Sanofi-Aventis U.S. LLC | BLA | Current |
| 0024-5903 | Praluent | alirocumab | Sanofi-Aventis U.S. LLC | BLA | Current |
| 0024-5903 | Praluent | alirocumab | Sanofi-Aventis U.S. LLC | BLA | Current |
| 0024-5903 | Praluent | alirocumab | Sanofi-Aventis U.S. LLC | BLA | Current |
| 0024-5903 | Praluent | alirocumab | Sanofi-Aventis U.S. LLC | BLA | Current |
| 0024-5903 | Praluent | alirocumab | Sanofi-Aventis U.S. LLC | BLA | Current |
| 0024-5904 | Praluent | alirocumab | Sanofi-Aventis U.S. LLC | BLA | Current |
| 0024-5904 | Praluent | alirocumab | Sanofi-Aventis U.S. LLC | BLA | Current |
| 0024-5904 | Praluent | alirocumab | Sanofi-Aventis U.S. LLC | BLA | Current |
| 0024-5904 | Praluent | alirocumab | Sanofi-Aventis U.S. LLC | BLA | Current |
| 0024-5904 | Praluent | alirocumab | Sanofi-Aventis U.S. LLC | BLA | Current |
| 0024-5904 | Praluent | alirocumab | Sanofi-Aventis U.S. LLC | BLA | Current |
| 0024-5904 | Praluent | alirocumab | Sanofi-Aventis U.S. LLC | BLA | Current |
| 0024-5904 | Praluent | alirocumab | Sanofi-Aventis U.S. LLC | BLA | Current |
| 0024-5904 | Praluent | alirocumab | Sanofi-Aventis U.S. LLC | BLA | Current |
| 0024-5904 | Praluent | alirocumab | Sanofi-Aventis U.S. LLC | BLA | Current |
| 0024-5904 | Praluent | alirocumab | Sanofi-Aventis U.S. LLC | BLA | Current |
| 0024-5904 | Praluent | alirocumab | Sanofi-Aventis U.S. LLC | BLA | Current |
| 61755-020 | Praluent | alirocumab | Regeneron Pharmaceuticals, Inc. | BLA | Current |
| 61755-020 | Praluent | alirocumab | Regeneron Pharmaceuticals, Inc. | BLA | Current |
| 61755-020 | Praluent | alirocumab | Regeneron Pharmaceuticals, Inc. | BLA | Current |
| 61755-020 | Praluent | alirocumab | Regeneron Pharmaceuticals, Inc. | BLA | Current |
| 61755-020 | Praluent | alirocumab | Regeneron Pharmaceuticals, Inc. | BLA | Current |
| 61755-021 | Praluent | alirocumab | Regeneron Pharmaceuticals, Inc. | BLA | Current |
| 61755-021 | Praluent | alirocumab | Regeneron Pharmaceuticals, Inc. | BLA | Current |
| 61755-021 | Praluent | alirocumab | Regeneron Pharmaceuticals, Inc. | BLA | Current |
| 61755-021 | Praluent | alirocumab | Regeneron Pharmaceuticals, Inc. | BLA | Current |
| 61755-021 | Praluent | alirocumab | Regeneron Pharmaceuticals, Inc. | BLA | Current |
| 72733-5901 | Praluent | alirocumab | Sanofi US Corporation | BLA | Current |
| 72733-5901 | Praluent | alirocumab | Sanofi US Corporation | BLA | Current |
| 72733-5901 | Praluent | alirocumab | Sanofi US Corporation | BLA | Current |
| 72733-5901 | Praluent | alirocumab | Sanofi US Corporation | BLA | Current |
| 72733-5901 | Praluent | alirocumab | Sanofi US Corporation | BLA | Current |
| 72733-5901 | Praluent | alirocumab | Sanofi US Corporation | BLA | Current |
| 72733-5901 | Praluent | alirocumab | Sanofi US Corporation | BLA | Current |
| 72733-5901 | Praluent | alirocumab | Sanofi US Corporation | BLA | Current |
| 72733-5901 | Praluent | alirocumab | Sanofi US Corporation | BLA | Current |
| 72733-5901 | Praluent | alirocumab | Sanofi US Corporation | BLA | Current |
| 72733-5901 | Praluent | alirocumab | Sanofi US Corporation | BLA | Current |
| 72733-5902 | Praluent | alirocumab | Sanofi US Corporation | BLA | Current |
| 72733-5902 | Praluent | alirocumab | Sanofi US Corporation | BLA | Current |
| 72733-5902 | Praluent | alirocumab | Sanofi US Corporation | BLA | Current |
| 72733-5902 | Praluent | alirocumab | Sanofi US Corporation | BLA | Current |
| 72733-5902 | Praluent | alirocumab | Sanofi US Corporation | BLA | Current |
| 72733-5902 | Praluent | alirocumab | Sanofi US Corporation | BLA | Current |
| 72733-5902 | Praluent | alirocumab | Sanofi US Corporation | BLA | Current |
| 72733-5902 | Praluent | alirocumab | Sanofi US Corporation | BLA | Current |
| 72733-5902 | Praluent | alirocumab | Sanofi US Corporation | BLA | Current |
| 72733-5902 | Praluent | alirocumab | Sanofi US Corporation | BLA | Current |
| 72733-5902 | Praluent | alirocumab | Sanofi US Corporation | BLA | Current |